CSTL — Castle Biosciences Share News
0.000.00%
Last trade - 00:00- $1.03bn
- $776.11m
- $344.23m
Brief: Castle Biosciences Announces Third Quarter 2022 Results
Castle Biosciences Inc reports results for the quarter ended in September - Earnings Summary
Castle Biosciences Inc expected to post a loss of 88 cents a share - Earnings Preview
Brief: Castle Biosciences - Decisiondx-SCC Clinical Utility Study Published In Cancer Investigation
Brief: Castle Biosciences Presents New Data From Collaboration With The National Cancer Institute’S (Nci) Surveillance, Epidemiology And End Results (Seer) Program
Castle Biosciences gains on positive data for Barrett's Esophagus Test results
Brief: Castle Biosciences Presents New Data Demonstrating The Impact Of Decisiondx®-Scc Test Results On The Management Of Medicare-Eligible Patients With Cutaneous Squamous Cell Carcinoma And One Or More Risk Factors
Brief: Updates From Decide Study Involving Decisiondx-Melanoma Test
Brief: Castle Biosciences Announces Publication Of Study For Treatment Of Patients With Cutaneous Melanoma
Brief: Castle Biosciences Sees FY Rev $255 Mln To $330 Mln
U.S. RESEARCH ROUNDUP- Avalara, Global Blood Therapeutics, Tyson Foods
Castle Biosciences Inc reports results for the quarter ended in June - Earnings Summary
Brief: Castle Biosciences Raises 2022 Revenue Guidance To $130-135 Mln From $118-123 Mln
Brief: Patients With Uveal Melanoma Tested With Decisiondx-Um Report Gaining Value From Test Results In Study Conducted In Collaboration With The Melanoma Research Foundation’S Cure Om Initiative
Brief: Collaborative Study With Melanoma Research Foundation Confirms Patients Diagnosed With Melanoma Desire Testing With Decisiondx-Melanoma
Brief: Castle Biosciences’ Decisiondx®-Melanoma Test Receives 2022 Medtech Breakthrough Award
Brief: Tissuecypher® Outperforms Pathologist Diagnoses When Predicting Progression In Patients Diagnosed With Barrett’S Esophagus With Low-Grade Dysplasia
Brief: Data Study Of Patients With High-Risk Cutaneous Squamous Cell Carcinoma Confirms Independent Risk-Stratification Performance Of Decisiondx-SCC
U.S. RESEARCH ROUNDUP- Applied Blockchain, Cheniere Energy, Roblox